Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05417776 · ClinicalTrials.gov registry record · Phase 2

Collagen-targeted PET Imaging for Early Interstitial Lung Disease

A Phase 2 study of Interstitial Lung Disease, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
Phase 2
Development phase
30
Enrollment target
1
Study location

NCT05417776 is a Phase 2 study of Interstitial Lung Disease that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 30 participants, below the 566-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05417776, a Phase 2 study of Interstitial Lung Disease, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
Phase 2
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to investigate the ability of \[68Ga\]CBP8 to detect collagen deposition in early interstitial lung disease.

Conditions Studied

Interventions

  • DRUG [68Ga]CBP8
  • DRUG Dotarem

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2022-09-28
Est. Completion 2026-04-01
Phase Phase 2

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT05417776

The ClinicalTrials.gov registry entry for NCT05417776 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 566-participant average among 36 other Interstitial Lung Disease trials with a reported enrollment target (95% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Interstitial Lung Disease appearing as the primary indexed condition, and to 2 interventions - of which [68Ga]CBP8 is the first listed.

NCT05417776 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05417776 about?

NCT05417776 is a clinical study titled "Collagen-targeted PET Imaging for Early Interstitial Lung Disease". The goal of this study is to investigate the ability of \[68Ga\]CBP8 to detect collagen deposition in early interstitial lung disease.

What is the current status of trial NCT05417776?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2022-09-28. Estimated completion is 2026-04-01.

What conditions does trial NCT05417776 study?

This clinical trial studies the following conditions: Interstitial Lung Disease.

What interventions are being tested in trial NCT05417776?

The interventions under investigation include: [68Ga]CBP8 (DRUG), Dotarem (DRUG).

Who is sponsoring clinical trial NCT05417776?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05417776 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Interstitial Lung Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.